Clinical Impact of Proton Pump Inhibitors and Other Co-medications on Advanced Melanoma Patients Treated With BRAF/MEK inhibitors.

While several studies reported the influence of co-medications on immune checkpoint therapy and chemotherapy, it remains poorly studied with targeted therapy. Targeted therapies inhibiting BRAF and MEK had significantly improved management of advanced melanoma with BRAFV600 mutation over the last decade, we aimed to investigate the possible influence of co-mediations on the efficacy and toxicity of these targeted therapies (TT).

https://www.ejcancer.com/article/S0959-8049(23)00779-7/fulltext?rss=yes

Source: European Journal of Cancer - December 9, 2023 Category: Cancer & Oncology Authors: Elo ïse Ramel, Sorilla Prey, Caroline Dutriaux, Emilie Gerard, Anne Pham-Ledard, Marie Beylot-Barry, Marie Kostine Tags: Current Perspective Source Type: research